Triple therapy antibiotic combination with proton pump inhibitor

This page covers all Triple therapy antibiotic combination with proton pump inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Helicobacter pylori bacterial ribosomes (amoxicillin and clarithromycin); H+/K+-ATPase (lansoprazole), H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole).

Targets

Helicobacter pylori bacterial ribosomes (amoxicillin and clarithromycin); H+/K+-ATPase (lansoprazole) · H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole)

Marketed (1)

• Amoxicillin-Clarithromycin-Lansoprazole · Fatma Zehra Arvas · Gastroenterology
  This triple-therapy combination eradicates Helicobacter pylori by combining two antibiotics that inhibit bacterial protein synthesis with a proton pump inhibitor that reduces gastric acid.

Phase 3 pipeline (1)

• CLA (Clarithro+Lanso+Amoxi) · Asofarma de México S.A de C.V. · Gastroenterology / Infectious Disease
  CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole).

Patent intelligence

• antibiotic combination with proton pump inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates